- Home
- PLRX vs PHAT Comparison
PLRX vs PHAT Comparison
Compare PLRX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- PHAT
- Stock Information
- Founded
- PLRX 2015
- PHAT 2018
- Country
- PLRX United States
- PHAT United States
- Employees
- PLRX N/A
- PHAT N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- PHAT Health Care
- Exchange
- PLRX Nasdaq
- PHAT Nasdaq
- Market Cap
- PLRX 641.5M
- PHAT 539.5M
- IPO Year
- PLRX 2020
- PHAT 2019
- Fundamental
- Price
- PLRX $14.69
- PHAT $8.50
- Analyst Decision
- PLRX Strong Buy
- PHAT Strong Buy
- Analyst Count
- PLRX 7
- PHAT 4
- Target Price
- PLRX $40.50
- PHAT $23.00
- AVG Volume (30 Days)
- PLRX 459.1K
- PHAT 992.3K
- Earning Date
- PLRX 11-07-2024
- PHAT 11-07-2024
- Dividend Yield
- PLRX N/A
- PHAT N/A
- EPS Growth
- PLRX N/A
- PHAT N/A
- EPS
- PLRX N/A
- PHAT N/A
- Revenue
- PLRX N/A
- PHAT $26,270,000.00
- Revenue This Year
- PLRX N/A
- PHAT $7,622.43
- Revenue Next Year
- PLRX N/A
- PHAT $236.87
- P/E Ratio
- PLRX N/A
- PHAT N/A
- Revenue Growth
- PLRX N/A
- PHAT N/A
- 52 Week Low
- PLRX $10.22
- PHAT $6.07
- 52 Week High
- PLRX $19.62
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- PLRX 56.15
- PHAT 36.67
- Support Level
- PLRX $13.14
- PHAT $7.81
- Resistance Level
- PLRX $15.27
- PHAT $8.56
- Average True Range (ATR)
- PLRX 0.75
- PHAT 0.59
- MACD
- PLRX 0.00
- PHAT 0.22
- Stochastic Oscillator
- PLRX 58.27
- PHAT 38.28
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.